<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-04-05T12:53:16Z</responseDate><request verb="GetRecord" identifier="oai:www.recercat.cat:2445/180474" metadataPrefix="rdf">https://recercat.cat/oai/request</request><GetRecord><record><header><identifier>oai:recercat.cat:2445/180474</identifier><datestamp>2025-11-19T10:49:07Z</datestamp><setSpec>com_2072_1057</setSpec><setSpec>col_2072_478781</setSpec><setSpec>col_2072_478816</setSpec><setSpec>col_2072_478917</setSpec></header><metadata><rdf:RDF xmlns:rdf="http://www.openarchives.org/OAI/2.0/rdf/" xmlns:ow="http://www.ontoweb.org/ontology/1#" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:ds="http://dspace.org/ds/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">
   <ow:Publication rdf:about="oai:recercat.cat:2445/180474">
      <dc:title>GDF15 mediates the metabolic effects of PPARβ/δ by activating AMPK</dc:title>
      <dc:creator>Aguilar-Recarte, David</dc:creator>
      <dc:creator>Barroso Fernández, Emma</dc:creator>
      <dc:creator>Gumà i Garcia, Anna Maria</dc:creator>
      <dc:creator>Pizarro Delgado, Javier</dc:creator>
      <dc:creator>Peña, Lucía</dc:creator>
      <dc:creator>Ruart, Maria</dc:creator>
      <dc:creator>Palomer Tarridas, Francesc Xavier</dc:creator>
      <dc:creator>Wahli, Walter</dc:creator>
      <dc:creator>Vázquez Carrera, Manuel</dc:creator>
      <dc:subject>Trastorns del metabolisme dels lípids</dc:subject>
      <dc:subject>Àcids grassos</dc:subject>
      <dc:subject>Receptors nuclears (Bioquímica)</dc:subject>
      <dc:subject>Glucosa</dc:subject>
      <dc:subject>Lipid metabolism disorders</dc:subject>
      <dc:subject>Fatty acids</dc:subject>
      <dc:subject>Nuclear receptors (Biochemistry)</dc:subject>
      <dc:subject>Glucose</dc:subject>
      <dc:description>Peroxisome proliferator-activated receptor β/ (PPARβ/) activates AMP-activated protein kinase (AMPK) and plays a crucial role in glucose and lipid metabolism. Here, we examined whether the beneficial effects of PPARβ/δ activation depended on growth differentiation factor 15 (GDF15), a stress response cytokine that regulates energy metabolism. Pharmacological PPARβ/δ activation increased GDF15 levels and ameliorated glucose intolerance, fatty acid oxidation, endoplasmic reticulum stress, inflammation and activated AMPK in HFD-fed mice, whereas these effects were abrogated by the injection of a GDF15 neutralizing antibody and in Gdf15-/- mice. The AMPK-p53 pathway was involved in the PPARβ/δ-mediated increase in GDF15, which in turn activated again AMPK. Finally, Gdf15-/- mice showed reduced AMPK activation in skeletal muscle, whereas GDF15 administration resulted in AMPK activation in this organ. Collectively, these data reveal a novel mechanism by which PPARβ/δ activation increases the levels of GDF15 via AMPK and p53, which in turn mediates the metabolic effects of PPARβ/δ by sustaining AMPK activation. Abbreviations: Acadm, acyl-CoA dehydrogenase medium chain; Acox, acyl-CoA oxidase; AMPK, AMP-activated protein kinase; ATF4, activating transcription factor 4; BiP/GRP78, Binding immunoglobulin protein/78-kDa glucose-regulated protein; CC, compound C; Chop, C/EBP homologous protein; Cpt-1, carnitine palmitoyl-transferase 1; eIF2eukaryotic translation initiation factor 2 ER, endoplasmic reticulum; ERK, extracellular signal-regulated kinase; FGF21, fibroblast growth factor 21; GDF15, growth differentiation factor 15; GFRAL, glial-derived neurotrophic factor receptor α-like; HFD, high-fat diet; Pdk4, pyruvate dehydrogenase kinase 4; IRS, insulin receptor substrate; PGC-1PPAR co-activator 1 PPAR peroxisome proliferator-activated receptor; SOCS3, suppressor of cytokine signaling 3; STAT3, signal transducer and activator of transcription 3; Vldlr, very-low density lipoprotein receptor.</dc:description>
      <dc:date>2021-10-07T09:22:36Z</dc:date>
      <dc:date>2021-10-07T09:22:36Z</dc:date>
      <dc:date>2021-07-16</dc:date>
      <dc:date>2021-10-07T09:22:36Z</dc:date>
      <dc:type>info:eu-repo/semantics/article</dc:type>
      <dc:type>info:eu-repo/semantics/publishedVersion</dc:type>
      <dc:relation>Reproducció del document publicat a: https://doi.org/10.1016/j.celrep.2021.109501</dc:relation>
      <dc:relation>Cell Reports, 2021, vol. 36, num. 6, p. 109501</dc:relation>
      <dc:relation>https://doi.org/10.1016/j.celrep.2021.109501</dc:relation>
      <dc:rights>cc-by (c) Aguilar-Recarte, David et al., 2021</dc:rights>
      <dc:rights>https://creativecommons.org/licenses/by/4.0/</dc:rights>
      <dc:rights>info:eu-repo/semantics/openAccess</dc:rights>
      <dc:publisher>Elsevier</dc:publisher>
      <dc:source>Articles publicats en revistes (Farmacologia, Toxicologia i Química Terapèutica)</dc:source>
   </ow:Publication>
</rdf:RDF></metadata></record></GetRecord></OAI-PMH>